Bevacizumab
Quick Overview
| Attribute | Value |
|---|---|
| Drug Name | Bevacizumab |
| DrugBank ID | DB00112 |
| KG Predictions | 180 |
| DL Predictions (≥0.7) | 0 |
| Evidence Level | L5 |
| NPRA Status | Approved |
Sample Brand Names in Malaysia
Predicted Indications
This drug has 180 knowledge graph predictions and 0 high-confidence deep learning predictions.
Top KG Predictions
| Indication | Source |
|---|---|
| peritoneum cancer | KG |
| hereditary breast ovarian cancer syndrome | KG |
| malignant epithelial tumor of ovary | KG |
| primary peritoneal carcinoma (disease) | KG |
| breast neoplasm | KG |
| metastatic malignant neoplasm in the colon | KG |
| squamous cell carcinoma of the corpus uteri | KG |
| breast cancer | KG |
| cervical cancer | KG |
| glioblastoma (disease) | KG |
FHIR Resources
Access drug data via FHIR R4 API:
- MedicationKnowledge:
/fhir/MedicationKnowledge/DB00112
Related Resources
| Resource | Link |
|---|---|
| DrugBank | View on DrugBank |
| PubMed | Search PubMed |
| ClinicalTrials.gov | Search Trials |
Disclaimer
Drug repurposing predictions are for research purposes only. These predictions have not been clinically validated and should not be used for medical decisions. Always consult healthcare professionals.
Drug repurposing predictions are for research purposes only. These predictions have not been clinically validated and should not be used for medical decisions. Always consult healthcare professionals.